Corporate Brochure

Transcription

Corporate Brochure

REC_BROCH_2016_INGLESE_Layout 1 30/05/16 15:39 Pagina 1
A LONG SUCCESS STORY. OVER 90 YE
1926 1926 Recordati was founded in Correggio
(Emilia, Italy). The company emerges from a small
apothecary which Giovanni Recordati (1898-1952)
transformed into an industrial concern:
the “Laboratorio Farmacologico Reggiano”.
1953 In a period of economic expansion and post-war
resurgence, Recordati moves the company to the current
site in Milan, the most important Italian economic centre.
Recordati specialties such as Antispasmina colica® (1927,
antispasmodic for the gastrointestinal tract), Solvobil®
(1930, laxative and colagenic), Tefamin® (1935, heart tonic,
diuretic and antihypertensive) and its associations,
Simpamina® (1938, stimulant) continued to perform well.
1961 An exclusive license agreement is signed
with Syntex Corporation (now part of Roche),
at that time at the leading edge of research into the study
and synthesis of steroidal hormones.
New original drugs are registered and commercialized
in a number of countries: Recordil® (1959, efloxate,
coronary vasodilator), Remeflin® (1962, dimefline,
respiratory analeptic) and Antoral® (1977, tibezonium
iodide, an oral antiseptic).
In 1973 flavoxate (Genurin®/ Urispas® and other brands),
a urinary anti-spasmodic still widely used,
was launched. It was the first drug synthesized and
developed in Italy to receive FDA approval in the USA.
1984 The company is listed on the Italian stock exchange
(Borsa Italiana, now part of the London Stock Exchange).
The development of the pharmaceutical business continues
with the introduction of new specialties and the launch
of another product originated from Recordati’s research,
Lomexin® (fenticonazole), a dermatological and
gynecological anti-mycotic, still widely used in clinical
practice in many countries.
1995 Recordati outlines its growth and development
strategy embarking on a process of internationalization.
A subsidiary was established in Spain, now called
Casen Recordati.
1997 First launch of Zanidip® (lercanidipine), a new
antihypertensive drug entirely discovered and developed
by Recordati.
1999 Recordati acquires the French pharmaceutical
company Doms Adrian to establish a Group direct presence
in the second largest pharmaceutical market in Europe.
2000 Expansion in France continues with the acquisition
of the Bouchara pharmaceutical group.
2001 The two French companies are merged and the
resulting subsidiary becomes Bouchara Recordati.
Conversion of all savings shares into ordinary shares
and subsequent 2:1 stock split (2001).
2002 The U.K. Medicines Control Agency granted a
Product License (marketing approval) for Zanidip®
(lercanidipine) 20 mg tablets.
2004 The pharmaceutical pipeline is considerably
strengthened through the launch of important drugs
in the cardiovascular, gastroenterology, CNS, and
respiratory therapeutic fields.
The 20mg strength of lercanidipine launched in a number
of countries including Germany, France and Australia.
2005 Acquisition of Merckle Recordati in Germany, now
Recordati Pharma. With this acquisition Recordati gains
access to the largest pharmaceutical market in Europe
and the third largest worldwide.
Establishment of Recordati Pharmaceuticals
in the United Kingdom and of Recordati Hellas
Pharmaceuticals in Greece.
Recordati establishes a presence in Ireland with
the opening of a new active pharmaceutical ingredients
plant in Ringaskiddy, County Cork. 4:1 stock split.
2006 Recordati enters the Portuguese pharmaceutical
market directly through the acquisition of the Grupo Jaba
companies, today Jaba Recordati.
A new original Recordati product is approved.
Zanipress®, a fixed combination of lercanidipine and
enalapril was approved for sale by BfArM (the German
medicines agency). This approval represents the
beginning of the process which will result in the
introduction of this new important product in all the
European markets and beyond.
2007 The first launch of Zanipress®, Recordati’s new
antihypertensive product which associates lercanidipine
and enalapril in a fixed combination, took place in
Germany. Recordati enters the orphan drug market
through the acquisition of Orphan Europe, a European
pharmaceutical group based in Paris dedicated to the
development, registration, marketing and distribution of
unique drug for the treatment of rare and orphan
diseases.
90 YEARS OF ACTIVITY.
2008 Recordati acquires the French companies FIC
and FIC Médical which are dedicated to the registration and
the promotion of pharmaceutical products in Russia and
other Commonwealth of Independent States (C.I.S.)
countries. Recordati sets the base from which it will
expand its activity into high growth markets.
Recordati also acquired Yeni Ilaç, a well-known
pharmaceutical company with headquarters near Istanbul
in Turkey, a market with high growth rates.
2009 Recordati acquires Herbacos-Bofarma, a
pharmaceutical company operating in the Czech and
Slovak markets.
2010 European Marketing Authorization obtained for the
medicinal products Urorec® and Silodyx™ 4 mg, 8 mg, hard
capsules, intended for treatment of the signs and symptoms
of benign prostatic hyperplasia (BPH).
Carbaglu® (carglumic acid) approved by the Food and Drug
Administration (FDA) in the U.S. for the treatment of NAGS
deficiency. Acquisition of ArtMed International, a company
dedicated to the promotion of pharmaceutical products in
Romania. Positive outcome of the Decentralized Procedure
for the approval of pitavastatin (Livazo®, Alipza® and other
brands) in Europe.
2011 Orphan Europe, the group’s wholly-owned subsidiary
dedicated to treatments for rare diseases, received
European approval to extend the use of Carbaglu®
(carglumic acid) to treat hyperammonaemia due to either of
the three main organic acidaemias.
The Group intensifies its strategy to grow in the emerging
markets of Central and Eastern Europe: Recordati Polska is
established in Poland and a second pharmaceutical
company is acquired in Turkey, Dr. F. Frik Ilaç A.S.. Recordati
acquires the brand and all rights to Procto-Glyvenol ® a
product indicated for the treatment of haemorrhoids.
Livazo® (pitavastatin) launched in Spain and in Portugal.
2012 Acquisition of the marketing authorizations, the
trademarks and additional assets concerning six OTC
pharmaceuticals for Germany.
Recordati reinforces its presence in Poland with the
acquisition of Farma-Projekt and consolidates its business
in Russia and other C.I.S. countries with the acquisition
of all rights to five well-known product lines including the
addition of a dedicated sales organization.
Acquisition in Italy of the leading oral care line of products
bearing the Dentosan® trademark.
An agreement was signed with Erytech Pharma for the
commercialization and distribution of Graspa® for the
treatment of Acute Lymphoblastic Leukemia (ALL) and
Acute Myeloid Leukemia (AML) in Europe.
Recordati acquires all rights concerning a portfolio of
products indicated for the treatment of rare and other
diseases in the United States of America which is now
marketed there by Recordati Rare Diseases.
2013 Recordati acquires Opalia Pharma S.A., a Tunisian
pharmaceutical company with headquarters in Ariana
(Tunis) and a modern cGMP certified production facility,
which represents a strategic platform to establish a direct
presence in North Africa with the objective of extending
coverage also to countries in Central Africa and
in the Gulf states.
The Group reinforces its presence in Spain, the fifth
pharmaceutical market in Europe, with the acquisition of
Laboratorios Casen Fleet S.L.U., a Spanish pharmaceutical
company with headquarters in Madrid, production
facilities in Utebo, Zaragoza, that markets drugs mainly
in the gastroenterological therapeutic area.
2014 An exclusive license agreement was entered into
with Apricus Biosciences Inc., San Diego U.S.A., for the
marketing and sales of Vitaros® (alprostadil), an innovative
topical product for the treatment of erectile dysfunction,
in certain European countries, Russia, Ukraine and the
Commonwealth of Independent States (C.I.S.), Turkey
and certain African countries. U.S. Food and Drug
Administration (FDA) granted approval of Orphan Europe’s
request for orphan drug designation for the use of
Carbaglu® (carglumic acid) in the treatment of organic
acidemias (OAs).
A license agreement with Plethora Solutions for the
commercialization of Fortacin™, a topical spray formulation
of lidocaine and prilocaine for the treatment of premature
ejaculation, in Europe, Russia, Commonwealth
of Independent States (C.I.S.), Turkey and certain countries
in North Africa was signed.
2015 The internationalization of our rare disease business
went ahead with the establishment of subsidiaries in Latin
America, and in particular in Brazil, Mexico and Colombia.
Furthermore, Carbaglu® (carglumic acid) was authorized
for sale by Health Canada as an adjunctive therapy for the
treatment of acute hyperammonaemia or as maintenance
therapy for chronic hyperammonaemia due to NAGS
deficiency in pediatric and adult patients.
1926 | 2016
1926 | 2016
FUTURE GROWTH STEMS FROM DEEP ROOTS.
All mentions and descriptions of Recordati prescription products are intended solely to inform
the reader of the general nature of the Company’s activities with the sole institutional objective
of presenting the Company and the Group. They are not intended to promote the use, or to
indicatethe advisability of using, Recordati prescription products, in compliance with existing law.
REC_BROCH_2016_ING_OK_Layout 1 06/06/16 11:29 Pagina 1
2 |
RECORDATI
RECORDATI
A RENOWNED INTERNATIONAL
PHARMACEUTICAL GROUP
Thanks to its flexibility
and to the established capability
of its management, the Recordati group
is able to operate successfully
in a market in continuous
evolution and to identify fitting
business opportunities as they arise.
A RENOWNED INTERNATIONAL PHARMACEUTICAL GROUP
| 3
A MODERN AND DYNAMIC INTERNATIONAL GROUP
Recordati is a modern and dynamic international pharmaceutical group
based in Milan, italy.
Recordati is listed on the Italian Stock Exchange (London Stock Exchange Group)
since 1984.
It has grown constantly since 1926 thanks to the success of its products and
to the implementation of a decisive internationalization policy through
a focused strategy of acquisitions and license agreements.
Recordati produces and promotes innovative medicines worldwide including both
products for primary care therapies and treatments for rare diseases.
In addition to the marketing of specialties generated by its original research, the Recordati
group is the european partner of leading international pharmaceutical companies.
4 |
A RENOWNED INTERNATIONAL PHARMACEUTICAL GROUP
RECORDATI IN A CHANGING MARKET
With subsidiaries in the main European countries, in U.S.A., in some Latin American
countries, in Russia and the Commonwealth of Independent States, in Turkey and in
Tunisia, Recordati is interested in developing its business both in the Central and Eastern
European countries and in the so-called MENA (Middle East and North Africa) countries
where pharmaceutical markets show potential for growth.
Recordati constantly enhances its therapeutic offering through the development
of its product pipeline mainly in the area of urological disorders and in the field
of rare diseases.
RECORDATI, A GROWING
COMMITMENT TO THE TREATMENT
OF RARE DISEASES
Recordati is committed to the improvement
of the quality of life of people suffering from rare
diseases and works together with patients and their
families, with doctors and with the support
of a highly specialized internal team.
The Recordati group operates worldwide through its dedicated subsidiaries Orphan
Europe and Recordati Rare Diseases who share the conviction that each person with a
rare disease has the right to the best possible treatment.
Recordati develops, produces and sells drugs for the treatment of rare diseases, and
operates worldwide in a highly specialized market with a significant growth potential.
RECORDATI
THE RECORDATI GROUP
BETWEEN PRESENT AND FUTURE
The proven ability for creating profitable partnerships with important players
in the pharmaceutical sector will continue to support the Recordati group
in its quest to identify new partners and finalize new license agreements
for the development of high value medicinal products.
A GROWING PRESENCE IN NEW MARKETS
In the future the Recordati group will continue its focus on the development of its
international business and in particular in pharmaceutical markets with growth potential
such as Russia, Eastern Europe, Turkey, Tunisia and countries around the Mediterranean.
Recordati will continue to concentrate its activity in Europe, which is the second largest
pharmaceutical market in the world, and to make its products for the treatment of rare
diseases available worldwide including the U.S.A., the first largest market, and some
Latin American countries.
| 5
6 |
THE RECORDATI GROUP BETWEEN PRESENT AND FUTURE
A RICHER PRODUCT PORTFOLIO
The launch of innovative new products, the enhancement of its product portfolio
with specialties from its own research and development or from targeted license
agreements or specific acquisitions, will boost the group’s growth.
The extensive geographical coverage, an efficient field force of medical representatives
and orphan drug specialists, the significant competence
in handling regulatory processes, the profound know-how in the handling
of highly specialized products, all make the Recordati group an ideal partner
for the development and marketing of new products in Europe.
THE RECORDATI GROUP BETWEEN PRESENT AND FUTURE
CONSTANT INVESTMENT IN RESEARCH AND INNOVATION
Recordati is committed towards the innovation and marketing of high value added
products and therefore constantly develops new medicines and believes research
and development is a fundamental basis for its growth.
Dedication and scientific rigor are always behind Recordati’s specialties
and self-medication products which are also produced with the highest levels
of quality and safety.
The “Arrigo Recordati International Prize for Scientific Research” is a further testimony
of the Recordati Group’s commitment to support the development
of new innovative therapies.
R&D EXPENSES
Millions of Euro
85.2
74.7
76.7
63.4
56.0
2011 2012 2013 2014 2015
| 7
8 |
RECORDATI
TODAY’S NUMBERS
2015 was a very favourable year for the group
and a number of initiatives were pursued
or the company’s future development.
REVENUE
1,047.7 millions of euro
NET INCOME
198.8 millions of euro
NET FINANCIAL POSITION
(88.7) millions of euro
SHAREHOLDERS‘ EQUITY
870.0 millions of euro
DIVIDEND
0.60 euro per share
EMPLOYEES
4,000
TODAY’S NUMBERS
REVENUE
Millions of Euro
1,047.7
INTERNATIONAL
BUSINESS GROWTH
TREND
OPERATING INCOME
Millions of Euro
| 9
OPERATING INCOME
AS % OF REVENUE
278.5
987.4
26.6%
79.8%
941.6
231.0
828.3
77.8%
762.0
195.4
163.5 167.0
75.7%
23.4%
73.5%
21.5%
20.8%
70.9%
2011 2012 2013 2014 2015
NET INCOME
20.2%
2011 2012 2013 2014 2015
NET INCOME
AS % OF REVENUE
Millions of Euro
198.8
2011 2012 2013 2014 2015
2011 2012 2013 2014 2015
DIVIDEND PER SHARE
BALANCE SHEET
Euro
At 31 December 2015
0.60
19.0%
18.56%
Current Liabilities
0.50
161.2
40.35%
Current Assets
22.22%
133.7
Non-Current
Liabilities
116.4 118.5
16.3%
0.33
0.30 0.30
59.65%
Non-Current
Assets
15.3%
59.22%
Shareholders’
Equity
14.3%
14.2%
2011 2012 2013 2014 2015
2011 2012 2013 2014 2015
2011 2012 2013 2014 2015
10 |
RECORDATI
GEOGRAPHICAL
PRESENCE
135
COUNTRIES
Subsidiaries
Branches and other forms of territorial presence
Countries where Recordati products are sold (under license or exported)
GEOGRAPHICAL PRESENCE
GEOGRAPHICAL COMPOSITION OF PHARMACEUTICAL SALES (First quarter 2016)
21.1% Italy
6.3% Spain
9.8% France
5.4% North Africa
8.8% USA
3.4% Portugal
8.3% Germany
2.8% Other West Europe
7.7% Turkey
2.7% Other CEE
6.6% Russia, Ukraine and other C.I.S.
17.1% Other International sales
| 11
12 |
RECORDATI
RECORDATI’S
SUCCESSFUL PRODUCTS
A number of innovative high value added specialties comprise
a large and qualified product portfolio.
The Recordati group:
makes available to healthcare professionals and patients numerous medicines
belonging to various therapeutic areas;
boasts an important presence in the areas of cardiovascular and urological disorders
for which it offers new treatments;
markets products originated by its own research and by specific license agreements
by promoting a wide range of innovative drugs.
RECORDATI’S SUCCESSFUL PRODUCTS
PHARMACEUTICAL SALES BY THERAPEUTIC AREA (2015)
16.9% Treatments for Rare Diseases
15.1%
Gastrointestinal and Metabolism
25.9% Cardiovascular
2.3%
Dermatology
3.7%
Ginecology
2.6%
Anti-infective
8.4%
Muscolo-skeletal, Analgesia
3.9%
Central Nervous System
6.7%
Respiratory
3.0%
Sense organs
9.7%
Urology
1.8%
Others
COMPOSITION OF REVENUE BY BUSINESS (2015)
40.3% Corporate Products
14.6% Treatments for Rare Diseases
16.9% OTC
23.6% Subsidiaries’ Local products
1.2%
Other Revenue
3.4%
Pharmaceutical Chemicals
| 13
14 |
CORPORATE PRODUCTS
Main specialties marketed by the group:
ZANIDIP® [CORIFEO®/LERCADIP®] (lercanidipine)
antihypertensive
ZANIPRESS® [ZANEXTRA®/LERCAPREL®/LERCARIL®]
(lercanidipine + enalapril) antihypertensive
UROREC® (silodosin)
benign prostatic hyperplasia
LIVAZO® [ALIPZA®] (pitavastatin)
hypercholesterolaemia
TERGYNAN®
gynecological infections
®
Sodio picosolfato - Magnesio ossido leggero - Acido citrico anidro
CITRAFLEET® and FOSFOSODA®
bowel evacuants
LOMEXIN® [FALVIN®] (fenticonazole)
antimycotic
HEXA LINE OF PRODUCTS (biclotymol)
antibacterial for infections of the oral cavity
PROCTO-GLYVENOL® (tribenoside)
haemorrhoids
URISPAS® [GENURIN®] (flavoxate)
urinary tract muscle relaxant
TRANSACT® LAT (flurbiprofen transdermal patch)
anti-inflammatory
RUPAFIN®/WYSTAMM® (rupatadine)
antihistamine
CASENLAX®/LAXBENE® and FLEET ENEMA®
constipation and bowel cleansing
KENTERA® (oxybutynin transdermal patch)
hyperactive bladder
OXYBUTYNIN TRANSDERMAL PATCH
Lopresor
®
LOPRESOR® (metoprolol)
antihypertensive
MUVAGYN®
vaginal dryness
VITAROS®/VIRIREC® (alprostadil)
erectile dysfunction
| 15
16 |
SUBSIDIARIES’ LOCAL PRODUCTS
Some products or product lines marketed locally by Recordati’s
subsidiaries detain prominent positions in their markets of reference.
GEOGRAPHICAL COMPOSITION OF PHARMACEUTICAL REVENUE
(2015)
54.4% Western Europe
10.2% Central and Eastern Europe
11.6%
Turkey and North Africa
8.1%
USA
15.7%
Others
In addition to its consolidated presence in the cardio-metabolic area,
Recordati in Italy offers innovative treatments in urology and for disorders
of and gastrointestinal system as well as modern analgesics.
In France Bouchara Recordati is the exclusive licensee for the production
and commercialization of methadone, a synthetic opioid analgesic,
used in disintoxication from opiates and in maintenance programmes.
The company has also developed an important international presence
in the Maghreb area and in French-speaking Africa and Asia.
A dynamic export and promotion business distributes its specialties
in more than 30 countries.
Recordati Pharma in Germany supplies first class products
to orthopaedic specialists and to gastroenterologists, in particular
as related to chronic inflammatory intestinal disorders such as
Crohn’s disease and ulcerative colitis.
| 17
18 |
Rusfic, Recordati Ukraine and FIC Médical, our organizations
operating in Russia, Ukraine and CIS markets have very successfully
developed the market for a product indicated for the topical
treatment of vaginal infections which boasts a leading position
in the class of gynaecological anti-infective and antiseptic drugs.
In Turkey Recordati Ilaç markets a diversified product portfolio
well appreciated by the practitioner, mainly comprising products
for the treatment of disorders of the urinary tract and other
urological disorders.
In Tunisia, Opalia Pharma, one of the largest local pharmaceutical
companies, markets branded generic drugs with leading products
in dermatology and in the gastrointestinal and respiratory
therapeutic areas.
RECORDATI
RECORDATI AND THE TREATMENT
OF RARE DISEASES
The acquisition and diffusion of specific scientific knowledge
is fundamental for the identification of a rare disease
and is of great importance in the research for new therapies.
www.recordatimalattierare.it
Rare diseases bring great suffering to millions of affected people
worldwide. A rare disease is defined as a condition that affects fewer
than 5 per 10,000 inhabitants in Europe or fewer than 200,000
Americans in the U.S.A..
There are more than 7,000 known rare diseases but today treatment
exists for only 200-300 of these.
| 19
20 |
RECORDATI AND THE TREATMENT OF RARE DISEASES
The Recordati group operates in the rare disease segment worldwide through
its dedicated subsidiaries Orphan Europe and Recordati Rare Diseases.
Orphan Europe operates globally through a network of subsidiaries in
Europe and in the Middle East and a number of marketing agreements.
It develops, produces and markets drugs exclusively for the treatment
of rare diseases.
Orphan Europe is one of the most important companies in Europe by
number of orphan drugs with marketing approval.
Recordati Rare Diseases is the company through which the group operates
in the rare disease segment in the U.S.A.
New subsidiaries were established in some Latin American countries.
Highly trained specialists and a scientific support team collaborate constantly
with doctors and healthcare professionals, with patient groups and families,
to treat and improve the quality of life of people suffering
from these diseases worldwide.
Thanks to a unique distribution system and to specialists dedicated to the
promotion and distribution of these products, the group is able to reach
patients in their home countries.
www.orphan-europe.com
The Recordati group
makes available to doctors
and their patients a team
of highly trained specialists
and a number
of specific drugs.
| 21
22 |
OUR DRUGS FOR RARE DISEASES
Normosang®/Panhematin®(USA) human hemin
Treatment of acute attacks of hepatic porphyria
Carbaglu®
carglumic acid
Treatment of hyperammonemia due to N-acetylglutamate
synthase deficiency (NAGS deficiency) and some organic
acidaemias (isovaleric acidaemia, methylmalonic
acidaemia and propionic acidaemia)
Cosmegen®
dactinomycin injectable
Treatment of three rare cancers
Pedea®/NeoProfen® (USA)
ibuprofene iv
Treatment of patent ductus arteriosus (PDA)
Cystadane®
betaine anhydrous
Treatment of homocystinuria
Cystadrops®
cysteamine chlorhydrate Submitted for approval for the treatment of ocular
manifestations of cystinosis
Cystagon®
cysteamine bitartrate
Treatment of nephropathic cystinosis
Vedrop®
tocofersolan
Treatment or prevention of vitamin E deficiency
in paediatric patients and adolescents suffering from
congenital or hereditary chronic cholestasis
Wilzin®
zinc acetate
Treatment of Wilson’s disease
Adagen®
pegademase bovine
Enzyme replacement therapy for the treatment of severe
combined immunodeficiency disease associated with
adenosine deaminase deficiency (SCID-ADA)
Recordati’s commitment to making its products available to patients suffering from rare
diseases was recognized by the National Organization for Rare Disorders (NORD)
in the U.S.A. with its 2011 “Corporate Award”. This important award was granted in
recognition of the introduction into the United States of Carbaglu®, the first specific
treatment approved by the FDA (Food and Drug Administration) for NAGS deficiency,
a very rare inherited metabolic disease.
The important results obtained by Orphan Europe (Recordati group) in improving the
diagnosis and management of rare diseases were recognized by EURORDIS (European
Organization for Rare Diseases) with an award presented during the celebration of the
2014 Rare Disease Day. The award also distinguishes its established track record in the
field of orphan drug development and its engagement with the rare disease community.
Orphan Europe achieves this through work to establish scientific networks, engaging
with patient organizations and its staff volunteering program.
| 23
24 |
The Recordati Rare Diseases Fondation d’entreprise targets specialized healthcare
professionals and its aim is to improve and to spread currently available knowledge
on rare diseases. The organization promotes scientific collaboration, the sharing
of experiences and knowledge among sector specialists and the development
of new ideas.
Every year the Academy proposes theoretical and practical courses as well as
e-learning online courses which aim to provide physicians, world-wide, with clinically
useful and the most up-to-date information concerning current knowledge
and recommendations for care.
Recordati is committed to supporting
families affected by these diseases through
the research and development
of new therapies and through the diffusion
of specific scientific knowledge within
the medical community.
RECORDATI
| 25
THE RECORDATI GROUP
AND ITS SELF-MEDICATION PRODUCTS
The Recordati group is also present in the self-medication
market segment with well-known brands. It is committed
to the improvement of quality of life by offering a choice
of successful products.
Recordati is on the constant look-out for new treatments
to offer patients and has extended
its OTC portfolio.
All Recordati’s pharmaceutical specialties and
self-medication products are characterized by high levels
of quality and safety in all countries.
26 |
RECORDATI
RESEARCH AND INNOVATION
AT RECORDATI
The introduction of new products, both through our discovery programs
as well as through alliances with other companies:
this is Recordati’s commitment and is a fundamental premise for its growth.
The Recordati group constantly develops new specialties originated either
internally or acquired through development agreements with other
pharmaceutical companies.
Commitment, scientific rigor, flexibility and highly specialized personnel
allow Recordati to develop new treatments and to count on an innovative
product pipeline.
Recordati’s research and development activities are mainly focused
on generating innovative treatments in the areas of urological
and rare diseases.
RESEARCH AND INNOVATION AT RECORDATI
| 27
PRODUCT DEVELOPMENT PIPELINE
Name
Originator
VITAROS®
Apricus
Erectile dysfunction
Approved by a number
of health authorities
in Europe
CARBAGLU®
Recordati
Organic acidemias (OA)
Approved in EU
Phase III in U.S.A.
CARBAGLU®
Recordati
Hyperammonaemia
New formulations
CYSTADROPS® Recordati
Ocular cystinosis
Filed in EU
FORTACIN™
Premature ejaculation
Variation of EU approval
completed
Cancer related pain in cases of resistance
or intolerance to opioids
Filed in France
Plethora Solutions
methadone
Indication
Development Status
CITRAFLEET®
Recordati/Casen
Preparation for colonoscopy in patients
at risk of intestinal polyps
MA variation
approved in EU
GRASPA®
Erytech
Acute lymphoblastic leukemia (ALL)
in patients with first recurrence
of Philadelphia chromosome negative ALL
Filed in EU
Acute myeloid leukemia (AML)
in patients >65 unfit for chemotherapy
Phase II b
Overactive bladder in patients
with spinal lesions
Phase I/II in EU
REC 0438
Recordati/UFPeptides
28 |
RECORDATI
PARTNERING
WITH THE RECORDATI GROUP
Thanks to its
capability in
developing successful
relationships,
Recordati has enacted
an intelligent policy
of partnering with
companies of high
standing in the
pharmaceutical
segment and made
targeted acquisitions
in markets
characterized
by high growth
potential thus
generating value for
itself and its partners.
Recordati has a strong track record in generating value
through partnerships with other pharmaceutical
companies, local or global players.
It is committed to generating further growth through
mutually beneficial R&D collaborations, license
agreements, acquisitions.
It covers directly around 80% of the European
pharmaceutical market and has a strong and growing
interest in new markets.
It has affiliates in Western Europe (Italy, France, Germany,
Greece, Portugal, Spain, United Kingdom and Ireland),
in Central Europe (Poland, the Czech Republic, Slovakia,
Romania), in Russia and the other CIS countries, in Ukraine
as well as in the U.S.A., in Turkey, in Tunisia and in some
Latin American countries.
PARTNERING WITH THE RECORDATI GROUP
The group disposes of a strong team of experienced sales
and marketing professionals.
Through its wholly owned subsidiary Orphan Europe and
its U.S. subsidiary Recordati Rare Diseases, Recordati is
also dedicated to the development and sale of drugs for
the treatment of rare diseases.
Recordati has proven R&D experience in developing
treatments for cardiovascular, urology disorders and rare
diseases.
Its proven capabilities in the management of regulatory
procedures and clinical trials in the EU, MENA (Middle
East and North Africa) and in the USA make Recordati an
ideal partner for the development and commercialization
of new products.
| 29
30 |
The extensive know-how acquired and dedicated industrial resources
allow the company to fully cover the manufacturing chain, from active
ingredient to finished product, in its own facilities in Italy, France, Ireland,
Spain, Turkey and Tunisia.
The financial solidity of the group allows it to support targeted
R&D investments.
The Group, which covers around 80% of the European pharmaceutical market
with a direct presence also in the USA, proposes itself as an ideal partner
for the development and commercialization of new products in its territories.
SELECTED PARTNERSHIPS
Licensor
Trademark
Active Ingredient
Rights for:
Actavis
Kentera®
oxybutynin TDS
29 European countries
Almirall
Cidine®
cinitapride
Spain
Amdipharm
TransAct®LAT
flurbiprofene LAT
Italy, Portugal
Apricus
Vitaros®
alprostadil
Spain, Ireland, Portugal, Greece,
some Eastern European
countries, Commonwealth of
Independent States, Ukraine,
Turkey, some African countries.
Ipsen
Tenstaten®
cicletanine
France
Kissei
Urorec®/Silodyx®/Silosin®
silodosin
Europe & Others
Kowa
Livazo®/Alipza®
pitavastatin
Europe (exc. UK, Germany)
Merck KGaA
Cardicor®
bisoprolol
Italy
MSD
Isocef®
ceftibuten
Italy
Ono-UCB
Alprostar®
PGE 1 Alpha
Italy
Plethora Solutions
Fortacin™
lidocaine+prilocaine
Europe, Russia, CIS, Turkey,
North Africa
Rottapharm/Madaus
Dermatrans®/Epinitril®
nitroglicerine TDS
Spain, France
Takeda
Peptazol®
pantoprazole
Italy
Uriach
Wystamm®/Rupafin®
rupatadine
France, Germany, Italy
| 31
32 |
RECORDATI
CORPORATE SOCIAL RESPONSIBILITY
ACTIVITIES
THE ARRIGO RECORDATI INTERNATIONAL PRIZE
FOR SCIENTIFIC RESEARCH
The Arrigo Recordati International Prize for Scientific Research was established
in the year 2000 in memory of the Italian pharmaceutical entrepreneur Arrigo
Recordati who strongly believed in the power of research to drive the development
of the pharmaceutical industry and provide products beneficial to public health.
The Prize is an international award which aims to promote scientific research
in the field of cardiovascular disease.
It consists in 100,000 Euros being awarded to a distinguished scientist
for his or her commitment and accomplishments in this area.
Each edition of the Prize, which is presented every two years, is dedicated to
a specific theme. More than 200 international societies and organizations specializing in
the areas of cardiology and internal medicine, are invited
to nominate candidates that they feel deserve the award.
The winner is chosen by a Jury composed of experts with high
international standing and is announced during an awards ceremony.
2017 ARRIGO RECORDATI INTERNATIONAL PRIZE
FOR SCIENTIFIC RESEARCH, NINTH EDITION.
• The theme chosen for the next edition of the Prize, which will take place in 2017, is:
“BIOLOGICAL THERAPIES FOR THE TREATMENT OF DISEASES AND CONDITIONS WITH
HIGH CARDIOVASCULAR RISK”.
• The winner of the Prize will be announced during an awards ceremony scheduled
to take place in Milan, Italy, on June 17, 2017, during the ESH (European Society of Hypertension)
Annual Meeting.
www.recordati.com/prize
CORPORATE SOCIAL RESPONSIBILITY ACTIVITIES
THE WINNERS OF PREVIOUS EDITIONS:
1st Edition
2001 HYPERTENSION
Giuseppe Mancia, Professor of medicine and chairmanof the department of clinical medicine,
prevention and applied biotechnologies of the University of Milan – Bicocca (Italy).
2nd Edition
2003 HEART FAILURE
Jay N. Cohn, Professor of Medicine, Cardiovascular Division, Department of Medicine, University
of Minnesota Medical School, Minneapolis - John K. Kjekshus, MD, PhD, Professor of Medicine,
Department of Cardiology, Rikshospitalet, University of Oslo, Oslo
3rd Edition
2005 SUDDEN CARDIAC DEATH
Leonard A. Cobb, MD, Hemeritus Professor, American College of Cardiology, Seattle WA, USA.
Peter J. Schawartz, MD, Professor and Chairman, Department of Cardiology, Policlinico San Matteo
IRCCS, Pavia, Italy Hein J. J. Wellens, MD, Honoré Retired Professor, University of Maastricht;
Director of Arrhythmology, Interventional Electrophysiology and Cardiology, University of
Maastricht, Maastricht, The Netherlands.
4th Edition
2007 INTERVENTIONAL CARDIOLOGY AND ISCHEMIC HEART DISEASE
Patrick W. Serruys, Professor of Interventional Cardiology, Thoraxcenter, Erasmus MC, Rotterdam,
The Netherlands
5th Edition
2009 IMAGING DIAGNOSTICS IN HEART DISEASE
Valentin Fuster, Director of Mount Sinai Heart - New York, U.S.A.
6th Edition
2011 PRENATAL CONGENITAL HEART DISEASE
Lindsay Allan, Consultant - King’s College, London, UK
7th Edition
2013 THE PIVOTAL ROLE OF MICROCIRCULATION IN SYSTEMIC AND ORGAN DISEASES
Filippo Crea, Professor of Cardiology - Università Cattolica
Policlinico “Agostino Gemelli” of Rome, Italy
8th Edition
2015 SECONDARY PREVENTION AND RISK REDUCTION STRATEGIES FOR PATIENTS
WITH CARDIOVASCULAR DISEASES.
John Joseph Valentine McMurray, Professor of Medical Cardiology and convener for clinical
research in the Institute of Cardiovascular & Medical Sciences at the University of Glasgow,
Scotland, UK.
Salim Yusuf, Professor of Medicine, Executive Director of the Population Health Research Institute
(PHRI), McMaster University, Hamilton, Canada.
| 33
34 |
CORPORATE SOCIAL RESPONSIBILITY ACTIVITIES
Every year Recordati supports a number of associations dedicated to assisting
sick people, to the improvement of patients’ quality of life, and to new
research projects. Social, cultural and environmental institutions who operate
seriously and with passion on a daily basis are generously assisted.
ASSISTANCE AND RESEARCH
• AISAC - Association for information on and the study
of Achondroplasia
• ANLAIDS - National AIDS Association
• UROMENDA (Hospital de Mendaro) Urology Association
• Asociación Neuroinvest (Hospital Virgen de la Macarena
Sevilla)
• Association for the development of Endocrinology and
Nutrition (Hospital Universitario Puerto Real Cádiz)
• Associazione Italiana GLUT1 - Association for GLUT 1
deficiency syndrome
• Association Chirurgie Robotisee et Mini Invasive
• Association Francaise Urologie
• Association pour l'etude des maladies de l’appareil urinaire
• Associazione Bianca Garavaglia - study and treatment of
pediatric tumors
• Associazione contro la leucemia e le altre emopatologie
maligne per la ricerca clinica e la terapia domiciliare Progetto EMO-CASA - leukemia and other hemooncology diseases
• Associazione Correre per la Speranza - Cancer association
• Cardiología Hospital Granollers
• Club de Reflexion des Cabinets et Groupes d'hepatogastroenterolgie
• Comitato Maria Letizia Verga - Study and treatment of
pediatric leukemia
• Conseil National Professionnel d'hepato-gastro-enterologie
• Deutsche Hochdruckliga - German association of
hypertension
• DKMS Deutsche Knochenmarkspenderdatei
gemeinnützige Gesellschaft mbH - support for activity by
the University of Leipzig on bone marrow typing
• Fondazione Benedetta D'Intino - Psychophysical suffering
in childhood
• Fondazione Manuli - Assistance for Alzheimer patients
• Fundació Clinic (Hospital Clínico Barcelona)
• Fundació Institut D'Investigació biomedica de Bellvitge
(IDIBELL)
• Fundación de Ayuda a la Investigación sobre Hipertensión
Arterial - research in hypertension
• IGOST Interdisziplinäre Gesellschaft für orthopädische /
unfallchirurgische und allgemeine Schmerztherapie Interdiciplinary association for pain management
• Institut Formation & Recherche en Endoscopie Digestive
• Sociedad Española de Diabetes
• Sociedad Española de Médicos de Atención Primaria
(SEMERGEN) - Spanish Society for primary care
• Societe Francaise de Cardiologie
• SuperAbile - Association for the rights of the disabled
CULTURE AND
THE ENVIRONMENT
• Associazione Culturale “G. DOSSETTI” - progetto “Officina
Malattie Rare” - Cultural projects on rare diseases
• Collegio Ghislieri - University college
• Coro San Pietro in Formis
• FAI - Italian Foundation for the Environment
• Fondazione Milano per la Scala
• Orchestra Sinfonica G. Verdi
RESEARCH
• Associazione Amici del Centro Dino Ferrari - research
in neuromuscular and neurovegetative diseases
• Associazione Amici di URI - Urological research institute
• Fondazione Ricerca e Innovazione su Ipertensione e
Protezione Cardiovascolare – Foundation for research
and innovation in hypertension and cardiovascular
protection
• The Arrigo Recordati International Prize for scientific
research
• Samuel e Barbara Sternberg Foundation - cancer
research and treatment
SOCIAL
• A.I.O.S.S - A.I.O.S.S - Association for the integration and
guidance of disadvantaged people
• Asiens vergessene Kinder - Association for social and
medical support of disadvantaged children and
adolescents
• Associazione Il Bruko - Volunteering and solidarity to help
the elderly and sick children
• Associazione Pensiero Celeste - support in perinatal
mourning
• Associazione Sesamo - support for people with
handicaps
• Associazione Tutela Malati Psichici (ATAP) - protection for
psychiatric patients
• BIR - Bambini in Romania - protection of minors
• Comunità di San Patrignano - support and rehabilitation
in drug addiction
• Deutsche Akademie für Sportmedizin - Academy for the
promotion of education in sports and rehabilitative
medicine
• Dynamo Camp - Recreation campus for children
suffering from serious chronic diseases
• Fond. Piero e Lucille Corti onlus - support for the Lacor
Hospital in Uganda
• Fondazione Nuovo Fiore in Africa - training activities
• GastroLiga - German Society of gastrointestinal diseases
• Lega del Filo d'Oro - support for the deaf and blind
• LifeNet Onlus - Association for the sanitary and social
support of populations in difficulty
• Naevus Italia Onlus - National Association of subjects
born with giant congenital melanocytic nevus
• Oeiras Luchapa Association - support for the homeless
• Ronda della Carità e Solidarietà - support for the poor
• Semi di Pace International - humanitarian society
• Solfraterno - support for poor families
• SSD Volare - support for the disabled
• Stiftung LebensBlicke - Foundation dedicated to early
diagnosis in colorectal cancer
• Temporary Foster Home in Barreiro
• Traumateam - Emergency medicine aid team
• Università Cattolica - Fund raising for African students
• Università degli Studi di Milano - CusMiBio - formative
project in secondary schools
• Volontariato Caritas Salesiani - help for the
disadvantaged
THROUGH ORPHAN EUROPE
AND RECORDATI RARE DISEASES,
THE RECORDATI GROUP ALSO,
SUPPORTS A NUMBER
OF OTHER ASSOCIATIONS:
• 1st University paediatric Dept
• ABASP (Association de l'avancement
des sciences pédiatriques)
• AFAG
• AIRG (Association pour l'Information
et la Recherche sur les maladies Rénales Génétiques)
• AJP (Association des Juniors en Pediatrie)
• ALLIAGE (Association Lariboisière des affectations
génétiques et Environementales du Cuivre et Autres
Metaux)
• American Heart Association
• American Porphyria Foundation
• ARCAMMHE (Association Regionale de Champagne
Ardenne pour le dépistage et la prévention des maladies
métaboliques des handicaps de l'enfant)
• ASCR (Association des services du CHU de Rouen)
• ASPIDA ZOIS
• Associazione Italiana Cistinosi
• Associazione Malattia di Wilson
• British Porphyria Association
• Centre français des porphyries
• Cystinosis Foundation
• Cystinosis Selbsthilfegruppe
• ERE (Enfance Recherche Espoir)
• Fondation maladies rares
• Fondation Necker
• Global Genes
• GrIP Onlus Gruppo Italiano Porfiria
• Healthwell Foundation
• Karathanas Brothers
• KIDIGO (Kidney Disease Improving
Clinical Outcomes)
• KRIKOS ZOIS
• National Urea Cycle Disorders
Foundation
• Network of Rare Blood Disorder Organizations Alberta, Canada
• NORD (National Organization for Rare Disorders)
• PESPA
• Rare Disease Legislative Advocates (RDLA)
• Raríssimas - Associação Nacional
de Deficiências Mentais e Raras
• Réseau Européen Maladies Rares
et Psychiatrie
• Serious Fun Camp
• SFEIM (La société française pour l’étude des erreurs
innées du métabolisme)
• Société Francophone pour l'Etude de la Maladie
de Wilson
RECORDATI
| 35
PHARMACEUTICAL CHEMICALS
Recordati uses
a broad range
of technologies to
produce competitively
maintaining
the highest quality
standards.
RECORDATI’S PHARMACEUTICAL
CHEMICALS BUSINESS FOCUSES ON:
satisfying the requirements of the pharmaceuticals business,
striving for maximum product quality,
strengthening its presence in highly regulated markets
(the United States, Europe and Japan),
safety of production processes,
protection of the environment,
health and safety in the workplace.
PHARMACEUTICAL CHEMICALS
Geographical breakdown of 2015 revenues
46.7% Europe
31.2%
America
16.9% Australasia
5.2%
Africa
36 |
RECORDATI
PRODUCTION SITES
The Recordati group has a number of production sites:
two dedicated to the production of pharmaceutical chemicals
and six for pharmaceutical manufacturing.
PHARMACEUTICAL CHEMICAL PLANTS
Recordati’s pharmaceutical chemical production sites are equipped
with modern plant and their research laboratories
are fitted with the latest equipment.
A vast range of technologies, skills and expertise in the field
of organic synthesis is employed to enable the quick and effective
study of new processes from the research stage through to final
industrialization.
PRODUCTION SITES
Campoverde d’Aprilia (Italy)
• This plant is one of the most important
producers in the world of verapamil,
phenytoin, papaverine and dimenhydrinate.
• Its main purpose is to supply the active
ingredients for the group’s proprietary
specialties, but it is also an established
independent producer of active ingredients
and intermediates for the pharmaceutical
industry internationally.
• The United States is the main market
for its production.
• The site covers a surface of 380,000 sq.m
with a covered area of 35,000 sq.m., and
produces approximately 650 metric tons per
year of finished goods and approximately
5,000 metric tons of semi-finished goods
are handled internally each year.
• Investments have been made for additional
productions, 12 new reactors and a latest
generation three stage distillation unit were
installed to further enhance production
capacity.
• It operates in compliance with Current
Good Manufacturing Practices (cGMP) and
in conformity with the most stringent
international environmental regulations.
The Plant Environmental Management
System is certified according to the UNI EN
ISO 14001:2004 by Det Norske Veritas Italia
(DNV).
Cork (Ireland)
• A dedicated plant was constructed in Cork
in Ireland to guarantee adequate and
continuous supplies of the active ingredient
lercanidipine, an important original
Recordati drug.
• This facility boasts automated process
control systems which ensure constant high
quality production.
• Received the 2012 National Energy
Efficiency Award which is promoted by the
sustainable Energy Authority of Ireland.
| 37
38 |
PRODUCTION SITES
PHARMACEUTICAL MANUFACTURING PLANTS
Recordati’s six pharmaceutical production facilities all operate in full compliance with
environmental protection regulations and with current Good Manufacturing Practices
(cGMP).
They are situated in Italy, France, Turkey, Spain, Tunisia and the Czech Republic.
• The Milan (Italy) site occupies a surface
of 21,000 sq.m. and produces 58 million
packs per year.
• The plant at Saint Victor (France) covers
a surface of 6,750 sq.m. and produces
35 million packs per year.
• The Turkish at Esenyurt site occupies a
surface of approximately 14,000 sq.m.
and produces 40 million packs per year,
of which 20% is dedicated to third party
production. This plant will soon be
replaced by the new manufacturing site
in Cerkezkoy which has a production
capacity of 80 million packs per year.
• The Spanish plant is situated near Zaragoza,
it occupies a surface of approximately
8,800 sq.m. and produces around 12 million
packs a year.
• The Tunisian plant is situated near Tunis,
it occupies a surface of approximately
7,500 sq.m. and produces around 17 million
packs a year for the local market and
for some of the countries in the Arabian
peninsula.
• The plant in the Czech Republic produces
a total of 2.5 million packs per year,
some of which for third parties.
RECORDATI
THE RECORDATI SHARE
Recordati is listed on the Italian Stock Exchange
(London Stock Exchange group) since 1984.
DIVIDEND PER SHARE
YEAR
PRINCIPAL SHAREHOLDERS
2006
€ 0.185
2007
€ 0.215
2008
€ 0.25
2009
€ 0.275
2010
€ 0.275
2011
€ 0.30
2012
€ 0.30
2013
€ 0.33
2014
€ 0.50
2015
€ 0.60
THE RECORDATI SHARE AT 31 DECEMBER 2015
(2015)
51.8%
46.2%
FIMEI*
Free Float
Listing:
Borsa Italiana Blue Chip
segment, healthcare
ISIN Code :
IT 0003828271
Ticker:
Bloomberg REC IM, Reuters RECI.MI
Indexes:
FTSE Italia Mid Cap Index
FTSE Italia All-Share Pharmaceuticals
& Biotechnology Index
ICB Code 4570
2.0%
Treasury Stock
* FIMEI is 100% owned
by the Recordati family
Share Capital:
209,125,156 common shares
Nominal value:
€ 0.125 per share
EPS (diluted):
€ 0.951
Dividend per share:
€ 0.60
| 39
May 2016
Produced by: Recordati S.p.A.
Concept and graphic design: Graphicamente Milano
Photos: Archivio Recordati, Niccolò Biddau, Riccardo Sarri, Shutterstock images
THE GROUP’S OFFICES
ITALY
IRELAND
RECORDATI S.p.A.
Via M. Civitali, 1 - 20148 Milan
Ph. +39 02 48787.1
Fax +39 02 40073747
www.recordati.com
RECORDATI IRELAND Ltd
Raheens East - Ringaskiddy
Co. Cork
Ph. +353 21 437 94 00
Fax +353 21 4379.264
Pharmaceutical chemical plant:
Via Mediana Cisterna, 4
04011 Campoverde di Aprilia (LT)
Ph. +39 06 92900010
Fax +39 06 92902016
MEXICO
INNOVA PHARMA S.p.A.
Via M. Civitali, 1 - 20148 Milan
Ph. +39 02 48787.1
Fax +39 02 48787235
COLOMBIA
RECORDATI RARE DISEASES
COLOMBIA S.A.S.
Cra 7 N° 127 - 48 Oficina 1202
Edificio 128 Centro Empresarial
Bogotá D.C. Colombia
Ph: +57 1 6472780; + 57 1 6474316
CZECH REPUBLIC AND SLOVAKIA
HERBACOS RECORDATI S.R.O.
Kutnohorská 11/57
109 00, Praga 10 - Dolní Mêcholupy
Ph. +420 227 200 722
Fax +420 227 200 777
Email: recordati@recordati.cz
www.recordati.cz
FRANCE
BOUCHARA-RECORDATI S.A.S.
LABORATOIRES BOUCHARA
RECORDATI S.A.S.
Immeuble "Le Wilson"
70, avenue du Général De Gaulle
92800 Puteaux
Ph. +33 1 45191000
Fax +33 1 47560246
Pharmaceutical plant:
Parc Mécatronic - 03410 Saint Victor
Ph. +33 4 70037900
Fax +33 4 70037890
GERMANY
RECORDATI PHARMA GmbH
Eberhard-Finckh-Str. 55
89075 Ulm
Ph. +49 731 7047.0
Fax +49 731 7047.297
www.recordati.de
RECORDATI RARE DISEASES S.A. de C.V.
Avenida Patriotismo 201 Piso 4-414,
Col. San Pedro de los Pinos C.P. 03800
Distrito Federal, Mexico
Ph. +52558852-7427
POLAND
RECORDATI POLSKA SP. Z O.O.
Ul. Królewska, 16
00-103 Varsavia
Ph. +48 22 206 84 50
Fax +48 22 206 84 51
PORTUGAL
JABA RECORDATI S.A.
LABORATORIOS CASEN FLEET S.L.U.
Lagoas Park, Edificio 5, Torre C, Piso 3
2740-298 Porto Salvo
Ph. +351 21 4329.500
Fax +351 21 9151.930
www.jaba-recordati.pt
ROMANIA
RECORDATI ROMÂNIA S.R.L.
28A Stelutei Street - Sector 1 - Bucarest
Ph. +40 21 667 17 41 - 2
Fax +40 31 405 57 42
www.recordati.ro
RUSSIA AND C.I.S.
RUSFIC LLC
World Trade Centre Office building 2,
entrance 7, offices 605-608
Krasnopresnenskaya emb. 12
Mosca, 123610, Russia
Ph. +7 495 258 20 06
Fax +7 495 258 20 07
Email: info@rusfic.com
FIC MEDICAL S.a.r.l.
Immeuble "Le Wilson"70,
avenue du Général de Gaulle
92800 Puteaux, Francia
Ph. +33 1 45 19 11 00
Fax +33 1 45 19 10 83
www.rusfic.ru
Plant:
Autovia Logroño km. 13,300
50180 Utebo, Zaragoza
Ph. +34.97.646.2626 / 91.659.15.50
Fax +34.97.677.1560
SWITZERLAND
RECORDATI S.A.
Piazza Boffalora, 4
6830 Chiasso (CH)
Ph. +41 91 682 6008
Fax +41 91 682 6009
TUNISIA
OPALIA Pharma
Z.I. Kalaat El Andalous
2022 Ariana
Ph. +216 70 559 070-064
Fax +216 70 559 184
Email: communication@opalia.com.tn
www.opaliapharma.com.tn
TURKEY
RECORDATI İLAÇ
Sanayi - ve Ticaret A.S.
Dogan Arasli Cad. No. 219
34510 Esenyurt-ISTANBUL
Ph. +90 212 620 28 50 Pbx
Fax +90 212 596 20 65
www.recordati.com.tr
UKRAINE
RECORDATI UKRAINE
40, Hlybochytska Str. - Kiev 04050
Ph. +380 44 351 18 63
Fax +380 44 351 18 64
UNITED KINGDOM
RECORDATI PHARMACEUTICALS Ltd
200 Brook Drive, Green Park, Reading
Berkshire RG2 6UB
Tel/Fax: +44 1491 576336
Email: customerservice@recordati.co.uk
UNITED STATES
RECORDATI RARE DISEASES
100 Corporate Drive
Lebanon, NJ 08833
Ph. +1 908 236 0888
Fax +1 908 236 0028
www.recordatirarediseases.com
SPAIN
ORPHAN EUROPE
CASEN RECORDATI S.L.
Via de las Dos Castillas, 33
Ática-Edificio 7
28224 Pozuelo, Madrid
Ph. +34 91 351 88 00 (Lab. Casen Fleet)
Fax +34 91 3518799
www.casenrecordati.com
Immeuble "Le Wilson"
70, avenue du Général De Gaulle
92800 Puteaux, Francia
Ph. +33 1 47 73 64 58
Fax +33 1 49 00 18 00
Email:contact@orphan-europe.com
GREECE
RECORDATI HELLAS
PHARMACEUTICALS S.A.
7, Zoodochou Pigis str
15231 K. Chalandri, Atene
Ph. +30 210 6773822
Fax +30 210 6773874
Industria Chimica e Farmaceutica S.p.A.
HEADQUARTERS
Via Matteo Civitali, 1 - 20148 Milan, Italy
Ph +39 02 48 787.1 - Fax +39 02 40 073 747
www.recordati.com

Corporate Brochure

Transcription

Similar documents

I`m helping to end MS by participating in the 2016 Jayman BUILT MS

The Board of Directors of Qatar Fuel (WOQOD) is pleased to invite

5 `S` Training Program at ABV-IIITM, Gwalior on 21.07.2016

4 star ALOE HOTEL, PAPHOS

loyola institute for ministry on-campus open house thursday, may 12

HALF OFF - Bavarian Inn

The Magic Wizard

KMEA Standards Handout

2016 MW Alliance Raffle - Manitowish Waters Alliance LTD

HERE - Perfect Shots Photography

Clachtoll Broch Icon of the North